• Ilyang Pharmaceutical’s Nov. 5, 2026, correction disclosed that Yangzhou Ilyang’s board voted to withdraw Supect’s Chinese marketing application.
• The joint venture plans to reapply for Chinese approval of the leukemia drug, radotinib, following replacement of its contract research organization.
• The correction identifies Xiamen Huaen Ilyang Investment as the 48% shareholder, replacing the Gaoyou government; Ilyang retains 52%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ilyang Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261105800789), on November 05, 2026, and is solely responsible for the information contained therein.